Real-time quantitative PCR (qPCR) is routinely used to detect minimal residual disease in
chronic myeloid leukemia patients. The absolute quantification with droplet digital PCR …

Simple Summary The introduction to clinical practice of a treatment-free remission approach
in chronic myeloid leukemia patients with a stable deep molecular response highlighted …

Measurement of BCR activator of RhoGEF and GTPase‐ABL proto‐oncogene 1, non‐
receptor tyrosine kinase (BCR‐ABL1) mRNA levels by reverse transcription quantitative …

Quantitative real-time PCR methods are commonly used to monitor BCR-ABL transcript
levels in patients with chronic myelogenous leukemia. However, standard techniques …

BCR-ABL1 fusion transcript is the minimal residual disease marker in chronic myeloid
leukemia; 2% of patients show unusual breakpoints generating atypical transcripts, not …

Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …

Accurate detection of BCR-ABL fusion transcripts at and below molecular response (MR) 4
(0.01% International Scale [IS]) is required for disease monitoring in patients with chronic …

Objective This study intended to establish a droplet digital PCR (dd‐PCR) for monitoring
minimal residual disease (MRD) in patients with BCR/ABL (P210)‐positive chronic myeloid …

Molecular monitoring of the BCR-ABL1 transcript for patients with chronic phase chronic
myeloid leukemia (CML) has become increasingly demanding. Real-time quantitative PCR …

BACKGROUND Tyrosine kinase inhibitors (TKIs) are the cornerstone of successful clinical
management of patients with chronic myeloid leukemia (CML). Quantitative monitoring of the …